No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison

Objectives: No specific treatment has been approved for COVID-19. Lopinavir/ritonavir (LPV/r) and hydroxychloroquine (HCQ) have been used with poor results, and a trial showed advantages of combined antiviral therapy vs. single antivirals. The aim of the study was to assess the effectiveness of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Gagliardini, Roberta, Cozzi-Lepri, Alessandro, Mariano, Andrea, Taglietti, Fabrizio, Vergori, Alessandra, Abdeddaim, Amina, Di Gennaro, Francesco, Mazzotta, Valentina, Amendola, Alessandra, D’Offizi, Giampiero, Palmieri, Fabrizio, Marchioni, Luisa, Piselli, Pierluca, Agrati, Chiara, Nicastri, Emanuele, Capobianchi, Maria Rosaria, Petrosillo, Nicola, Ippolito, Giuseppe, Vaia, Francesco, Girardi, Enrico, Antinori, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100580/
https://www.ncbi.nlm.nih.gov/pubmed/33967755
http://dx.doi.org/10.3389/fphar.2021.621676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8100580/
https://www.ncbi.nlm.nih.gov/pubmed/33967755
http://dx.doi.org/10.3389/fphar.2021.621676

Ejemplares similares